REVACCINATION WITH DIFFERENT COVID-19  VACCINE; SUSPECTED COVID-19; This spontaneous report received from a patient via other manufacturer (Pfizer) concerned an adult female. The patient's height, and weight were not reported. The patient's concurrent conditions included: penicillin allergy, and other pre-existing medical conditions included: Patient was not pregnant at time of vaccination. The patient previously received covid-19 vaccine ad26.cov2.s (Dose number in series 1) (first dose) (suspension for injection, route of admin not reported, batch number: 1805020 expiry: UNKNOWN) dose was not reported, 1 total administered on 09-MAR-2021, 17:00 at left arm for covid-19 prophylaxis. It was unknown whether patient had any adverse events following vaccination with first dose of covid-19 vaccine ad26.cov2.s. (Dose number in series 1). It was unknown whether patient had any adverse events following vaccination with covid-19 vaccine ad26.cov2.s (Dose number in series 1). The patient additionally received non-company suspect vaccine included Spikevax (elasomeran) (Moderna)(Dose number in series 2) (second dose) (batch number: 939904 expiry: UNKNOWN, form of admin, route of admin, and were not reported) dose was not reported, administered on 24-OCT-2021 at left arm for covid-19 prophylaxis. It was unknown whether patient had any adverse events following vaccination with second dose of Spikevax (elasomeran) (Moderna) (Dose number in series 2). The patient additionally received non-company suspect vaccine included Spikevax (elasomeran) (Moderna)(Dose number in series 3) (third dose) (batch number: A57415B expiry: UNKNOWN, form of admin, route of admin, and were not reported) dose was not reported, administered on 10-JUN-2022 at left arm for covid-19 prophylaxis. It was unknown whether patient had any adverse events following vaccination with third dose of Spikevax (elasomeran) (Moderna) (Dose number in series 3). The patient additionally received non-company suspect vaccine included Spikevax (elasomeran) (Moderna)(Dose number in series 4) (fourth dose) (batch number: 1805020 expiry: UNKNOWN, form of admin, route of admin, and were not reported) dose was not reported, administered on 10-SEP-2022 at left arm for covid-19 prophylaxis which was revaccination with different COVID-19 vaccine (Dose number in series 4). Concomitant medications included bupropion, Unisom (diphenhydramine hydrochloride), estradiol, levothyroxine, losartan, and Valacyclovir (valaciclovir) for unspecified indication. On an unspecified date in 2022, the patient had COVID-19 for which patient had non-company suspect Paxlovid (form of admin, route of admin, and batch number were not reported, expiry: unknown) dose was not reported, administered from 28-NOV-2022 to 03-DEC-2022 for Covid-19 treatment. On 06-DEC-2022 at 18:00 (evening), the patient started experiencing rebound symptoms (suspected COVID-19 infection), required 2 more 5-day isolation periods (Dose number in series 4) and symptoms resolved on 23-DEC-2022 The action taken with covid-19 vaccine ad26.cov2.s, elasomeran, elasomeran, elasomeran was not applicable and with paxlovid was drug withdrawn. The patient recovered from suspected covid-19 on 23-DEC-2022, and the outcome of revaccination with different covid-19 vaccine was not reported. This report was non-serious.